Horikoshi T, Onodera H, Eguchi H, Hanada N, Fukuzawa K, Takahashi M, Ishihara K, Ikeda S
Department of Dermatology, Sapporo Medical University, Japan.
Br J Dermatol. 1996 Jan;134(1):130-3.
We report the successful treatment of a patient with plaque-stage mycosis fungoides with long-term and intravenous administration of recombinant human interferon-gamma (IFN-gamma) and discuss the possible mechanisms of this therapy. A 55-year-old female patient had been resistant to existing treatments and had suffered repeated exacerbations over a 5-year period. Four weeks after initiation of 2 x 10(6) U/day of IFN-gamma, a > 10% decrease in the affected surface area was noted. Twenty-two weeks after the administration of 228 x 10(6) U of IFN-gamma, complete remission (CR) was obtained. The CR continued for 13 weeks, but this was followed by an exacerbation. The second CR was obtained after the IFN-gamma dosage was increased to 16 x 10(6) U/week. The dosage was then gradually reduced by 2-4 x 10(6) U every 2 or 3 months. She was treated with a total dose of 2814 x 10(6) of IFN-gamma. She has been followed up for more than 6 years, and there has been no recurrence of mycotic skin lesions nor any visceral involvement. During therapy, no serious side-effects were noted. Long-term administration of IFN-gamma is useful for the treatment of patients with intractable mycosis fungoides. A gradual decrease in the dose of IFN-gamma is important for maintaining remission.
我们报告了1例斑块期蕈样肉芽肿患者通过长期静脉注射重组人干扰素-γ（IFN-γ）成功治愈的病例，并讨论了该疗法可能的作用机制。1例55岁女性患者对现有治疗耐药，5年来病情反复加重。开始使用2×10⁶ U/天的IFN-γ治疗4周后，发现受累表面积减少>10%。给予228×10⁶ U的IFN-γ治疗22周后，获得完全缓解（CR）。CR持续了13周，但随后病情加重。将IFN-γ剂量增加至16×10⁶ U/周后获得第二次CR。然后每2或3个月逐渐减少2 - 4×10⁶ U的剂量。她接受的IFN-γ总剂量为2814×10⁶ 。对她进行了6年多的随访，皮肤真菌病损未复发，也无任何内脏受累。治疗期间未观察到严重副作用。长期给予IFN-γ对治疗难治性蕈样肉芽肿患者有效。逐渐减少IFN-γ剂量对维持缓解很重要。
